BB
SGMO

BB Biotech’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

BB Biotech’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$25.3M Buy
2,650,000
+1,300,000
+96% +$13.3M 0.64% 30
2018
Q4 		$15.5M Buy
+1,350,000
New +$16.8M 0.5% 31

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BB Biotech's SGMO Position: Q1 2019 in Review

BB Biotech increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 96% in Q1 2019, buying an estimated $13.3M and bringing the position to 2,650,000 shares worth $25.3M. The position accounts for 0.64% of the portfolio, ranked #30.

BB Biotech first reported a position in SGMO in Q4 2018 and has held it in 2 quarters since. 187 funds tracked by Wall St. Rank hold SGMO as of Q1 2019.

  • BB Biotech held 2,650,000 shares of SANGAMO THERAPEUTICS INC worth $25.3M as of Q1 2019.
  • BB Biotech bought 1,300,000 SANGAMO THERAPEUTICS INC shares in Q1 2019, an estimated $13.3M.
  • SANGAMO THERAPEUTICS INC made up 0.64% of BB Biotech's portfolio in Q1 2019, its #30 holding.
  • BB Biotech first reported a position in SANGAMO THERAPEUTICS INC in Q4 2018 and has held it in 2 quarters since.
  • 187 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.